"After intensive preparations and great commitment at our Norwegian trial center, we are now ready to start recruiting patients for the phase I/II study of our first drug candidate, ItolDC-028. The step into clinical phase is the most important milestone so far in the development of our unique cell therapy, to develop a product that can treat or prevent the development of antibodies against the important treatment with coagulation factor VIII (FVIII)", says
For further information, please contact:
Phone: +46 70 37 47 156
Email: christina.herder@idogen.com
Certified Advisor:
The information was submitted for publication, through the agency of the contact persons set out above, on 21 September, 2022,at
The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
https://news.cision.com/idogen/r/idogen-has-received-approval-from-the-regional-ethics-committee-to-conduct-a-clinical-phase-i-iia-st,c3634042
https://mb.cision.com/Main/12368/3634042/1628956.pdf
(c) 2022 Cision. All rights reserved., source